You are here

FDA Approves Tecentriq for Adults With Extensive-Stage Small Cell Lung Cancer

Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC

The FDA has approved atezolizumab (Tecentriq, Genentech) in combination with carboplatin and etoposide for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).

The approval was based on results from the IMpower133 study which demonstrated that atezolizumab combined with chemotherapy significantly extended the lives of patients with ES-SCLC compared to chemotherapy alone. In addition, the combination treatment significantly lowered the risk of disease worsening or death compared to chemotherapy alone.

ES-SCLC is a highly aggressive, difficult-to-treat form of lung cancer with few treatment advances over the last two decades. According to the American Cancer Society, approximately 70% of people with SCLC are diagnosed with ES-SCLC.

Atezolizumab is also approved in combination with bevacizumab, paclitaxel, and carboplatin for the initial treatment of adults with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations. In addition, Atezolizumab is approved for adults with metastatic NSCLC with disease progression during or after platinum-containing chemotherapy.

IMpower133, a phase 3, multicenter, double-blinded, randomized placebo-controlled study, evaluated the efficacy and safety of atezolizumab in combination with chemotherapy (carboplatin and etoposide) versus chemotherapy (carboplatin and etoposide) alone in chemotherapy-naïve adults with ES-SCLC.

The most common adverse reactions in people receiving atezolizumab plus chemotherapy were fatigue/asthenia, nausea, alopecia, decreased appetite, constipation, and vomiting.

Atezolizumab is also approved to treat urothelial carcinoma and triple-negative breast cancer.

Source: Genentech, March 18, 2019

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs